---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-014892"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2022-06-13T23:59:59+00:00"
generated_at: "2026-06-25T02:23:44.938317+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# UroGen shareholders reject say-on-pay and compensation policy; approve equity plan increase

## Summary
- Advisory vote on executive compensation failed: 5.7M against vs 4.2M for.
- Amendment to compensation policy under Israeli law not approved: 2.5M for, 4.9M against.
- Equity plan amendment (increase by 400K shares) approved narrowly: 5.3M for, 4.5M against.
- PricewaterhouseCoopers ratified as independent auditor with 14.2M votes for.
- All six director nominees elected, with Arie Belldegrun receiving 7.5M votes for.

## SEC filing metadata
- accession: 0001437749-22-014892
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2022-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000143774922014892/0001437749-22-014892-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000143774922014892/urgn20220610_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-014892
- JSON: https://secwatch.observer/filing/0001437749-22-014892.json
- Plain text: https://secwatch.observer/filing/0001437749-22-014892.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.